Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US7172749B2 · kind B2 · utility
1Cited by
6References
135Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 11, 2003 |
| Grant date | Feb 6, 2007 |
| Priority date | — |
| Expiry date | Mar 29, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.